Cisplatin
- Generic Name
- Cisplatin
- Brand Names
- Platinol
- Drug Type
- Small Molecule
- Chemical Formula
- Cl2H6N2Pt
- CAS Number
- 15663-27-1
- Unique Ingredient Identifier
- Q20Q21Q62J
- Background
Cisplatin, cisplatinum or cis-diamminedichloroplatinum(II) (CDDP) is a platinum-based chemotherapy drug used to treat various types of cancers, including sarcomas, some carcinomas (e.g. small cell lung cancer, and ovarian cancer), lymphomas and germ cell tumors. It was the first member of its class, which now also includes carboplatin and oxaliplatin.
- Indication
For the treatment of metastatic testicular tumors, metastatic ovarian tumors and advanced bladder cancer.
- Associated Conditions
- Advanced Ovarian Cancer, Ovarian Cancer Metastatic, Advanced Bladder cancer, Advanced Testicular cancer, Metastatic Testicular cancer
- Associated Therapies
- -
Intrathecal Radioimmunotherapy, Radiation Therapy, and Chemotherapy After Surgery in Treating Patients With Medulloblastoma
- First Posted Date
- 2003-04-09
- Last Posted Date
- 2020-05-11
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Target Recruit Count
- 6
- Registration Number
- NCT00058370
- Locations
- 🇺🇸
Memorial Sloan-Kettering Cancer Center, New York, New York, United States
🇺🇸Herbert Irving Comprehensive Cancer Center at Columbia University Medical Center, New York, New York, United States
Chemotherapy and Radiation Therapy With or Without Efaproxiral in Treating Patients With Stage III Non-Small Cell Lung Cancer
- Conditions
- First Posted Date
- 2003-03-07
- Last Posted Date
- 2013-05-10
- Lead Sponsor
- Spectrum Pharmaceuticals, Inc
- Registration Number
- NCT00055887
- Locations
- 🇨🇦
CHUS-Hopital Fleurimont, Fleurimont, Quebec, Canada
🇺🇸Schiffler Cancer Center, Wheeling, West Virginia, United States
🇨🇦Centre Hospitalier Universitaire de Quebec, Quebec City, Quebec, Canada
Tipifarnib, Gemcitabine, and Cisplatin in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer
- First Posted Date
- 2003-03-07
- Last Posted Date
- 2013-06-04
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 48
- Registration Number
- NCT00055757
- Locations
- 🇺🇸
Mayo Clinic, Rochester, Minnesota, United States
Hospitalization Rates of Patients With Non-Small Cell Lung Cancer Treated With Gemcitabine and Either Cisplatin or Carboplatin
- Conditions
- First Posted Date
- 2003-03-07
- Last Posted Date
- 2013-09-20
- Lead Sponsor
- The Christie NHS Foundation Trust
- Target Recruit Count
- 400
- Registration Number
- NCT00055965
- Locations
- 🇬🇧
Christie Hospital NHS Trust, Manchester, England, United Kingdom
S0121, Neoadjuvant Carboplatin, Paclitaxel, and Gemcitabine Followed by Cisplatin and Radiation Therapy in Treating Patients With Locally Advanced or Recurrent Carcinoma of the Urothelium
- Conditions
- First Posted Date
- 2003-03-07
- Last Posted Date
- 2013-01-31
- Lead Sponsor
- SWOG Cancer Research Network
- Target Recruit Count
- 7
- Registration Number
- NCT00055835
- Locations
- 🇺🇸
Cleveland Clinic Taussig Cancer Center, Cleveland, Ohio, United States
🇺🇸MBCCOP - Gulf Coast, Mobile, Alabama, United States
🇺🇸CCOP - Columbus, Columbus, Ohio, United States
Combination Chemotherapy and Radiation Therapy With/Without Surgery In Patients With Stage II/III Bladder Cancer
- Conditions
- Interventions
- First Posted Date
- 2003-03-07
- Last Posted Date
- 2018-06-15
- Lead Sponsor
- Radiation Therapy Oncology Group
- Target Recruit Count
- 97
- Registration Number
- NCT00055601
- Locations
- 🇺🇸
Utah Cancer Specialists at UCS Cancer Center, Salt Lake City, Utah, United States
🇺🇸LDS Hospital, Salt Lake City, Utah, United States
Cisplatin and Gemcitabine Compared With Observation in Treating Patients Who Have Undergone Surgery for Bladder Cancer
- Conditions
- First Posted Date
- 2003-02-06
- Last Posted Date
- 2013-12-18
- Target Recruit Count
- 700
- Registration Number
- NCT00054626
- Locations
- 🇮🇹
Ospedale Civile Trapani, Trapani, Italy
🇮🇹Ospedale Amedeo Savoia, Turin, Italy
🇮🇹Istituto Nazionale Riposo e Cura Anziani Istituto, Ancona - AN, Italy
Chemotherapy and Radiation Therapy With or Without Surgery in Treating Patients With Stage I Cancer of the Cervix
- Conditions
- First Posted Date
- 2003-02-06
- Last Posted Date
- 2013-04-11
- Lead Sponsor
- Gynecologic Oncology Group
- Registration Number
- NCT00054067
- Locations
- 🇺🇸
Jonsson Comprehensive Cancer Center, UCLA, Los Angeles, California, United States
🇺🇸University of Chicago Cancer Research Center, Chicago, Illinois, United States
🇺🇸Ireland Cancer Center, Cleveland, Ohio, United States
S0216, Combination Chemotherapy and RT in Treating Patients With Stage III or Stage IV Head and Neck Cancer
- Conditions
- First Posted Date
- 2003-02-06
- Last Posted Date
- 2011-07-25
- Lead Sponsor
- SWOG Cancer Research Network
- Registration Number
- NCT00054054
- Locations
- 🇺🇸
MBCCOP - Gulf Coast, Mobile, Alabama, United States
🇺🇸CCOP - Atlanta Regional, Atlanta, Georgia, United States
🇺🇸Veterans Affairs Medical Center - Chicago (Westside Hospital), Chicago, Illinois, United States
Radiation Therapy and Chemotherapy in Treating Patients With Locally Advanced Cervical Cancer
- Conditions
- Interventions
- First Posted Date
- 2003-02-06
- Last Posted Date
- 2014-12-31
- Lead Sponsor
- Gynecologic Oncology Group
- Target Recruit Count
- 11
- Registration Number
- NCT00054444
- Locations
- 🇺🇸
MetroHealth Medical Center, Cleveland, Ohio, United States
🇺🇸Arthur G. James Cancer Hospital and Solove Research Institute at Ohio State University Medical Center, Columbus, Ohio, United States
🇺🇸University of Chicago Comprehensive Cancer Center, Chicago, Illinois, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.